Last reviewed · How we verify
Placebo for Tesamorelin
A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 trial of tesamorelin (active comparator not specified in query).
At a glance
| Generic name | Placebo for Tesamorelin |
|---|---|
| Sponsor | Theratechnologies |
| Modality | Small molecule |
| Therapeutic area | Clinical Trial Control |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It allows researchers to distinguish between the therapeutic effects of the actual drug and effects due to patient expectation or natural disease progression. In this Phase 3 trial, placebo serves as the comparator arm against tesamorelin, a growth hormone-releasing hormone (GHRH) analog.
Approved indications
- Control arm in Phase 3 trial of tesamorelin (active comparator not specified in query)
Common side effects
Key clinical trials
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (PHASE2)
- TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy (PHASE3)
- Tesamorelin Effects on Liver Fat and Histology in HIV (NA)
- The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment (PHASE1)
- Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® (PHASE4)
- Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese (PHASE2)
- Effects of Growth Hormone Releasing Hormone in HIV (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Tesamorelin CI brief — competitive landscape report
- Placebo for Tesamorelin updates RSS · CI watch RSS
- Theratechnologies portfolio CI